Sharon Huang - FuelCell Energy | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

HC-7366, a Potent GCN2 Activator, Complements Belzutifan, a HIF-2α Antagonist, by Providing Combination Benefit in Belzutifan-Sensitive Models and Monotherapy Activity in Belzutifan-Resistant Models

Michael E. Stokes,Feven Tameire, Paulina Wojnarowicz,Sho Fujisawa,Crissy Dudgeon,Sharon Huang, Nick Collette,Ben Harrison, Ashley LaCayo, Xiaohong Qiu, Takashi Kangas,Weiyu Zhang,Jeremy Drees,David Surguladze, Eric S. Lightcap,Nandita Bose

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Abstract 4615: HC-7366, a Potent GCN2 Activator, Complements Belzutifan, a HIF-2⍺ Antagonist, by Providing Combination Benefit in Belzutifan-Sensitive Models and Monotherapy Activity in Belzutifan-Resistant Models

Michael E. Stokes,Feven Tameire,Paulina Wojnarowicz,Sho Fujisawa,Crissy Dudgeon,Sharon Huang,Nick Collette,Ben Harrison,Ashley LaCayo,Xiaohong Qiu,Takashi Kangas,Weiyu Zhang,Jeremy Drees,David Surguladze,Eric S. Lightcap,Nandita Bose

Cancer Researchno. 6_Supplement (2024): 4615-4615

引用0浏览0引用

Supplementary Table ST3 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Michael E. Stokes,Veronica Calvo,Sho Fujisawa,Crissy Dudgeon,Sharon Huang,Nupur Ballal,Leyi Shen,Jennifer Gasparek,Matthew Betzenhauser,Simon J. Taylor,Kirk A. Staschke,Alan C. Rigby,Mark J. Mulvihill,Nandita Bose,Eric S. Lightcap,David Surguladze

openalex（2023）

引用0浏览0引用

Abstract 4010: Inhibition of PERK by HC-5404 Sensitizes Clear Cell Renal Cell Carcinoma Tumor Models to Anti-Angiogenic Tyrosine Kinase Inhibitors

Michael E. Stokes,Veronica Calvo,Crissy Dudgeon,Sho Fujisawa,Sharon Huang,Leyi Shen,Nupur Ballal, Joe McGinley,David Liu,Mark J. Mulvihill,Alan C. Rigby,Nandita Bose,Eric S. Lightcap,David Surguladze

CANCER RESEARCH（2023）

引用0浏览0引用

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

CLINICAL CANCER RESEARCHno. 23 (2023): 4870-4882

引用0浏览0WOS引用

Supplementary Fig. S5 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

Michael Stokes,Verónica Calvo,Sho Fujisawa,Crissy Dudgeon,Sharon Huang,Nupur Ballal, Licong Shen,Jennifer Gasparek,Matthew J. Betzenhauser, S. Taylor,Kirk A. Staschke,Alan C. Rigby,Mark J. Mulvihill,Nandita Bose,Eric S. Lightcap,David Surguladze

openalex（2023）

引用0浏览0引用

Supplementary Table ST1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

crossref（2023）

引用0浏览0引用

Supplementary Fig. S1 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

openalex（2023）

引用0浏览0引用

Supplementary Fig. S4 from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors

crossref（2023）

引用0浏览0引用

Abstract A30: Activation of GCN2 by HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and in Combination with Venetoclax in AML Models

Feven Tameire, Paulina M. Wojnarowicz,Sho Fujisawa,Sharon Huang, Owen Reilly,Crissy Dudgeon, Nicholas Collette,Jeremy Drees,Kathryn Bieging-Rolett,Takashi O Kangas,Weiyu Zhang,Maria Fumagalli,Iman Dewji,Yunfang Li,Anissa SH Chan,Xiaohong Qiu,Ben Harrison,Ashley LaCayo,Kirk A. Staschke,Alan C. Rigby,Savithri Ramurthy,Eric S. Lightcap,David Surguladze,Nandita Bose

Blood Cancer Discoveryno. 3_Supplement (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn